# FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

> **NCT00161889** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 615 (—)

## Conditions studied

- Encephalitis, Tick-borne

## Interventions

- **BIOLOGICAL:** Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)

## Key facts

- **NCT ID:** NCT00161889
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** 2002-08
- **Target enrollment:** 615 (—)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161889, "FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00161889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*